Indirect-response model for the time course of leukopenia with anticancer drugs*

Hironobu Minami, Yasutsuna Sasaki, Nagahiro Saijo, +4

Clinical Pharmacology & Therapeutics

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11

Y Sasaki, Yasushi Yoshida, Kenichi Sudoh, +6

Japanese Journal of Cancer Research

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of <scp>K</scp>anto CML study group

Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, +15

American Journal of Hematology

Molecular ResponsesDasatinib TreatmentImmunologyCml Study GroupTumor Biology +18

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma

Hidetsugu Kawai, Kiyoshi Ando, Dai Maruyama, +18

Cancer Science

Clinical ImmunologyImmunologyImmunoeditingPathologyPhase Ii Study +15

Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11

Toshimichi Miya, Tomoyuki Goya, Hirofumi Fujii, +5

Investigational New Drugs

ObesityMetabolic SyndromeBody CompositionMedicineBody Mass Index +8

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

Kana Miyazaki, Naoko Asano, Tomomi Yamada, +21

Haematologica

ImmunologyPathologyPhase Ii StudyPharmacotherapyMetronomic Chemotherapy +17

Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice

Hironobu Minami, Kenji Kawada, Yasutsuna Sasaki, +7

Cancer Science

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study

Yuho Najima, Chikashi Yoshida, Noriyoshi Iriyama, +16

Leukemia Research

Cancer ImmunosurveillanceImmune Cell DevelopmentT-regulatory CellImmunologyTumor Immunity +12

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, +15

American Journal of Hematology

ImmunodeficienciesImmunologyImmunotherapyImmune SystemMyeloid Neoplasia +15

Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan

Kuniaki Itoh, Yasutsuna Sasaki, Yoshifumi Miyata, +5

Cancer Chemotherapy and Pharmacology

OncologyChemoprevention StrategyMedicinePotential PitfallsClinical Trials +9